Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 11/20 | 0.39 |
| ▸ | PPARG | P37231 | 9/20 | 0.39 |
| ▸ | PPARA | Q07869 | 7/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744882 | 1.00 | TDP1 (0.41) | TDP1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL1746365 | 0.92 | PPARD (0.47) | TDP1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL1746362 | 0.92 | PPARD (0.47) | TDP1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL1746364 | 0.92 | PPARD (0.47) | TDP1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL2510139 | 0.90 | PPARD (0.48) | TDP1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL2510142 | 0.90 | PPARD (0.48) | TDP1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL1745112 | 0.90 | PPARD (0.48) | TDP1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL1746571 | 0.89 | PPARD (0.48) | TDP1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL1744324 | 0.89 | TSHR (0.53) | TDP1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL1744421 | 0.89 | PPARD (0.46) | TDP1TSHRHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2386540-A1 | Novel compounds, their preparation and use | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110245244-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-10-06 | — | — | US | disclosed |
| US-7943613-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245244-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | PPARG, PPARA, PPARD | TDP1 3870/4885TSHR 1294/4885HTR2A 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.